IMOVANE (zopiclone) TABLET 7.5MG: restriction of indications

Sanofi-aventis would like to inform healthcare professionals about the new restriction of the indication to “short-term” treatment of insomnia and additional recommendations on the duration of treatment. These risk minimisation measures are intended to promote the proper use of zopiclone and limit the risk of abuse and drug dependence. The IMOVANE package insert has been updated with the above information. Please refer to the letter for details.

 
 
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under 'For Healthcare Professionals’.

Step 2: Click on 'Restricted Content' and log in via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’.

Step 4: Click on the Drug Alert tab to view the DHCPLs.